Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Publication year range
1.
Rev Med Brux ; 17(3): 136-9, 1996 Jun.
Article in French | MEDLINE | ID: mdl-8766585

ABSTRACT

We report the case of a 70 years old woman who developed a thrombotic thrombocytopenic purpura. Despite a treatment with corticoids and high doses IV gammaglobulins, the patient developed seizures. Treatment with plasma exchanges combined with plasma infusions allowed recovery. The authors review the clinical and biological aspects as well as the pathogeny of the disease. The authors insist on the importance of the plasma exchanges in the treatment of this disease.


Subject(s)
Purpura, Thrombotic Thrombocytopenic/therapy , Aged , Blood Cell Count , Drug-Related Side Effects and Adverse Reactions , Female , Humans , Infections/complications , Neoplasms/complications , Plasma Exchange , Purpura, Thrombotic Thrombocytopenic/blood , Purpura, Thrombotic Thrombocytopenic/etiology
2.
Haematologica ; 79(6): 550-6, 1994.
Article in English | MEDLINE | ID: mdl-7896216

ABSTRACT

Acquired hemophilia is a very rare disease characterized by the presence of an autoantibody (mainly IgG) to factor VIII, with a clinical presentation resembling hemophilia A. It is associated with various autoimmune or dermatologic diseases, pregnancy, cancer, or drug ingestion, but in almost 50% of patients no underlying disorder is found. The treatment of acquired hemophilia is particularly complex because response to therapy is unpredictable. If an acute hemorrhage occurs despite preventive measures, two complementary strategies must be employed: stopping the bleeding and decreasing the factor VIII inhibitor with human or porcine factor VIII, DDAVP, prothrombin complex concentrates, intravenous immunoglobulin, immunosuppression, or by extracorporeal removal of the inhibitor. Autoantibody titer, previous response to a given treatment, and severity of clinical presentation must be taken into account when choosing between these different therapeutic options, which must often be associated.


Subject(s)
Autoantibodies/immunology , Factor VIII/immunology , Hemophilia A/etiology , Adult , Aged , Blood Coagulation Factors/therapeutic use , Combined Modality Therapy , Deamino Arginine Vasopressin/therapeutic use , Factor VIII/therapeutic use , Female , Hemophilia A/immunology , Hemophilia A/therapy , Hemorrhage/etiology , Hemorrhage/therapy , Humans , Immunoglobulin G/immunology , Immunoglobulins, Intravenous/therapeutic use , Immunosuppressive Agents/therapeutic use , Male , Middle Aged , Plasmapheresis
SELECTION OF CITATIONS
SEARCH DETAIL
...